title: HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells.
abstract: Tumor cells can move as individual cells in two interconvertible modes: mesenchymal mode and amoeboid mode. Cytoskeleton rearrangement plays an important role in the interconversion. Previously, we reported that HAb18G/CD147 and annexin II are interacting proteins involved in cytoskeleton rearrangement, yet the role of their interaction is unclear. In this study we found that the depletion of HAb18G/CD147 produced a rounded morphology, which is associated with amoeboid movement, whereas the depletion of annexin II resulted in an elongated morphology, which is associated with mesenchymal movement. The extracellular portion of HAb18G/CD147 can interact with a phosphorylation-inactive mutant of annexin II and inhibit its phosphorylation. HAb18G/CD147 inhibits Rho signaling pathways and amoeboid movement by inhibiting annexin II phosphorylation, promotes membrane localization of WAVE2 and Rac1 activation by way of the integrin-FAK-PI3K/PIP3 signaling pathway, and promotes the formation of lamellipodia and mesenchymal movement.
  
  
  CONCLUSIONS
  These results suggest that the interaction of HAb18G/CD147 with annexin II is involved in the interconversion between mesenchymal and amoeboid movement of hepatocellular carcinoma cells.
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology, National Key Discipline of Cell Biology, Fourth Military Medical University, Xi'an, PR China.
authors.forename: Pu
authors.initials: P
authors.lastname: Zhao
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Shi-Jie
authors.initials: SJ
authors.lastname: Wang
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Yu
authors.forename: Juan
authors.initials: J
authors.lastname: Tang
authors.forename: Wan
authors.initials: W
authors.lastname: Huang
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
authors.forename: Hong-Yong
authors.initials: HY
authors.lastname: Cui
authors.forename: Yun-Shan
authors.initials: YS
authors.lastname: Guo
authors.forename: Jan
authors.initials: J
authors.lastname: Tavernier
authors.forename: Si-He
authors.initials: SH
authors.lastname: Zhang
authors.forename: Jian-Li
authors.initials: JL
authors.lastname: Jiang
authors.forename: Zhi-Nan
authors.initials: ZN
authors.lastname: Chen
mesh_terms: D017306:Annexin A2 / Q000378:metabolism*; D051926:Basigin / Q000502:physiology*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000276:immunology*; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D010766:Phosphorylation; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D020830:rac1 GTP-Binding Protein / Q000378:metabolism / Q000502:physiology*; D020742:rhoA GTP-Binding Protein / Q000378:metabolism / Q000502:physiology*
chemical_list: D017306:Annexin A2; C497886:BSG protein, human; D051926:Basigin; D020830:rac1 GTP-Binding Protein; D020742:rhoA GTP-Binding Protein